论文部分内容阅读
自从万络因为在腺瘤息肉预防APPROVe(adenomatous polyp.prevention on Vioxx)临床试验中发现的安全性问题而退出全球市场以后,非类固醇类抗炎药(NSAIDs)和COX-2抑制剂药物的心血管安全问题一直都让人担忧。然而全球仍有数以百万计的需要依靠缓解疼痛治疗才能达到可以接受的生活质量的患
Since Vanuatu exited the global market due to safety issues found in the clinical trial of APPROVe (adenomatous polyp. Prevention on Vioxx), the heart of non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitor drugs Vascular safety issues have always been of concern. However, millions of patients worldwide still need to rely on pain relief to achieve an acceptable quality of life